|
Symbol
MNMD
|
Exchange
NASDAQ
|
CIK
1813814
|
Currency
USD
|
Country
USA
|
Sector
LIFE SCIENCES
|
Industry
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
|
Address
1166 ALBERNI STEET, SUITE 1604, VANCOUVER, BC, CA
|
FiscalYearEnd
December
|
OfficialSite
https://www.mindmed.co
|
LatestQuarter
2024-06-30
|
MarketCapitalization
448057000
|
EBITDA
-80931000
|
PEGRatio
None
|
PERatio
None
|
BookValue
2.803
|
DividendPerShare
None
|
DividendYield
None
|
EPS
-2.04
|
RevenuePerShareTTM
0
|
ProfitMargin
0
|
OperatingMarginTTM
0
|
ReturnOnEquityTTM
-0.663
|
ReturnOnAssetsTTM
-0.276
|
RevenueTTM
0
|
GrossProfitTTM
0
|
DilutedEPSTTM
-2.04
|
QuarterlyEarningsGrowthYOY
0
|
AssetType
Common Stock
|
Name
Mind MedicineÂ Inc
|
Description
Mind Medicine (MindMed) Inc., a psychedelic medicine biotechnology company, discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is headquartered in New York, New York.
|
QuarterlyRevenueGrowthYOY
0
|
AnalystTargetPrice
26.25
|
AnalystRatingHold
0
|
AnalystRatingSell
0
|
AnalystRatingStrongSell
0
|
TrailingPE
-
|
ForwardPE
-
|
PriceToSalesRatioTTM
-
|
PriceToBookRatio
2.218
|
EVToRevenue
-
|
EVToEBITDA
-6.57
|
Beta
2.357
|
52WeekHigh
12.22
|
50DayMovingAverage
5.99
|
200DayMovingAverage
7.12
|
AnalystRatingStrongBuy
3
|
52WeekLow
2.41
|
SharesOutstanding
73332000
|
ExDividendDate
None
|
DividendDate
2020-02-27
|
AnalystRatingBuy
6
